Indication
Progression
4 clinical trials
5 products
1 drug
Clinical trial
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)Status: Recruiting, Estimated PCD: 2024-12-31
Product
BMF-219Clinical trial
To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Lung Tumors and the Investigation of Its Mechanism of Action.Status: Recruiting, Estimated PCD: 2026-11-30
Product
PropofolProduct
SevofluraneClinical trial
A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)Status: Active (not recruiting), Estimated PCD: 2025-11-10
Product
TMZDrug
AtezolizumabClinical trial
Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2026-05-20
Product
Everolimus